Reportlinker Adds Urinary Incontinence (UI) - Drug Pipeline Analysis and Market Forecasts to 2016

NEW YORK, April 1 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Urinary Incontinence (UI) - Drug Pipeline Analysis and Market Forecasts to 2016

http://www.reportlinker.com/p0185949/Urinary-Incontinence-UI---Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html

Urinary Incontinence (UI) - Drug Pipeline Analysis and Market Forecasts to 2016

Summary

GlobalData, the industry analysis specialist's new report, "Urinary Incontinence– Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global urinary incontinence market. The report identifies the key trends shaping and driving the global urinary incontinence market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global urinary incontinence sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.

Scope

The report provides information on the key drivers and challenges in the global UI market. It includes:

- Annualized global UI market revenues data from 2001 to 2009, forecast for seven years to 2016.

- Key geographies covered in this report include the US, the UK, Italy, Spain, Germany, France and Japan.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include acetylcholine antagonists/blockers, muscarinic receptor antagonists, beta-3 adrenoceptor antagonists, calcium influx inhibitors and intracellular calcium modulators, nonpeptide d-receptor agonists, neuronal serotonin and norepinephrine reuptake inhibitors, vanilloid receptor agonists, beta-3 adrenergic receptor agonists, noradrenaline reuptake inhibitors and NK1 receptor antagonists.

- Analysis of the current and future market competition in the global UI market. The key market players covered are Pfizer Inc., Allergan Inc., Kissei Pharmaceuticals and Astellas Pharma.

- An insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- The key topics covered include a strategic competitor assessment, a market characterization, unmet needs and implications for the future UI market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global urinary incontinence market.

- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global urinary incontinence market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

1 Table of contents

1 Table of contents 3

1.1 List of Tables 5

1.2 List of Figures 5

2 UI Therapeutics Market: Market Characterization 6

2.1 Overview 6

2.2 UI Therapeutics Market Size 7

2.3 UI Therapeutics Market Forecast and CAGR 8

2.4 Drivers and Barriers for the UI Therapeutics Market 9

2.4.1 Drivers for the UI Therapeutics Market 9

2.4.2 Barriers for the UI Therapeutics Market 9

2.5 Opportunity and Unmet Need 9

2.6 Key Takeaway 10

3 UI Therapeutics Market: Competitive Assessment 11

3.1 Overview 11

3.2 Strategic Competitor Assessment 11

3.3 Product Portfolio for Major Marketed Products in the UI Therapeutics Market 12

3.3.1 Detrol/Detrol LA (Tolterodine tartrate) 12

3.3.2 Ditropan (Oxybutynin chloride) 14

3.3.3 Enablex (Darifenacin) 15

3.3.4 Sanctura XR (Trospium Chloride) 16

3.3.5 Toviaz (Fesoterodine Fumarate) 17

3.3.6 VESIcare (Solifenacin Succinate) 18

3.4 Key Takeaway 20

4 UI Therapeutics Market: Pipeline Assessment 21

4.1 Overview 21

4.1.1 Technology Trends Analytical Framework 21

4.2 UI Therapeutics – Promising Drugs under Clinical Development 22

4.3 Molecule Profiles for Promising Drugs under Clinical Development 23

4.3.1 Botulinum Toxin A 23

4.3.2 YM178 24

4.4 UI Therapeutics Market - Pipeline Assessment by Mechanism of Action 24

4.5 UI Therapeutics Market - Pipeline Assessment by Clinical Phases of Development 25

4.5.1 UI Therapeutics – Phase III Clinical Pipeline 26

4.5.2 UI Therapeutics – Phase II Clinical Pipeline 26

4.5.3 UI Therapeutics – Phase I Clinical Pipeline 27

4.5.4 UI Therapeutics – Preclinical Pipeline 27

4.6 Discontinued/Suspended Drugs for UI 27

5 UI Therapeutics Market: Implications for Future Market Competition 28

6 UI Therapeutics Market: Key Players in the UI Therapeutics Market 29

6.1 Allergan Inc. 29

6.1.1 Overview 29

6.1.2 Financial Performance 29

6.1.3 Business Description 30

6.1.4 Urology Pipeline Portfolio 31

6.1.5 UI Pipeline Portfolio 31

6.2 Astellas Pharma 32

6.2.1 Overview 32

6.2.2 Financial Performance 33

6.2.3 Business Description 33

6.2.4 Urology Pipeline Portfolio 34

6.2.5 UI Pipeline Portfolio 34

6.3 Kissei Pharmaceuticals 35

6.3.1 Overview 35

6.3.2 Financial Performance 35

6.3.3 Business Description 35

6.3.4 Urology Pipeline Portfolio 36

6.3.5 UI Pipeline Portfolio 36

6.4 Pfizer Inc. 36

6.4.1 Overview 36

6.4.2 Financial Performance 37

6.4.3 Business Description 37

6.4.4 Urology Pipeline Portfolio 38

6.4.5 UI Pipeline Portfolio 38

7 UI Therapeutics Market: Appendix 39

7.1 Definitions 39

7.2 Acronyms 39

7.3 Research Methodology 39

7.4 Coverage 40

7.5 Secondary Research 40

7.6 Primary Research 41

7.7 Models 41

7.8 Forecasts 41

7.9 Expert Panels 42

7.10 GlobalData Consulting 42

7.11 Contact Us 42

7.12 Disclaimer 42

1.1 List of Tables

Table 1: UI Therapeutics Market, Global, Revenues ($m), 2001-2009 8

Table 2: UI Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016 9

Table 3: UI Therapeutics Market, Global, Clinical Study Details of Detrol LA, 2010 14

Table 4: UI Therapeutics Market, Global, Clinical Study Details of Ditropan XL, 2010 15

Table 5: UI Therapeutics Market, Global, Clinical Study Details of Enablex, 2010 16

Table 6: UI Therapeutics Market, Global, Clinical Study Details of Toviaz, 2010 18

Table 7: PAD Therapeutics Market, Global, Major Marketed Products Comparison in the PAD Therapeutics Market , 2010 20

Table 8: UI Therapeutics Market, Global, Most Promising Molecules under Clinical Development, February 2010 22

Table 9: UI Therapeutics Market, Global, Phase III Clinical Pipeline, 2010 26

Table 10: UI Therapeutics Market, Global, Phase II Clinical Pipeline, 2010 26

Table 11: UI Therapeutics Market, Global, Phase I Clinical Pipeline, 2010 27

Table 12: UI Therapeutics Market, Global, Preclinical Pipeline, 2010 27

Table 13: UI Therapeutics Market, Global, List of Discontinued Drugs for UI, 2010 27

Table 14: UI Therapeutics Market, Global, Allergan Inc. Urology Pipeline Portfolio, 2010 31

Table 15: UI Therapeutics Market, Global, Allergan Inc. UI Pipeline Portfolio, February 2010 31

Table 16: UI Therapeutics Market, Global, Astellas Pharma Urology Pipeline Portfolio, 2010 34

Table 17: UI Therapeutics Market, Global, Astellas Pharma UI Pipeline Portfolio, 2010 34

Table 18: UI Therapeutics Market, Global, Kissei Pharmaceuticals Urology Pipeline Portfolio, 2010 36

Table 19: UI Therapeutics Market, Global, Kissei Pharmaceuticals UI Pipeline Portfolio, 2010 36

Table 20: UI Therapeutics Market, Global, Pfizer Inc. Urology Pipeline Portfolio, 2010 38

Table 21: UI Therapeutics Market, Global, Pfizer Inc. UI Pipeline Portfolio, February 2010 38

1.2 List of Figures

Figure 1: UI Therapeutics Market, Global, Revenues ($m), 2001-2009 8

Figure 2: UI Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016 8

Figure 3: UI Therapeutics Market, Global, Opportunity and Unmet Need in the UI Therapeutics Market, 2010 10

Figure 4: UI Therapeutics Market, Global, Strategic Competitor Assessment of the Major Marketed Products in UI Therapeutics Market, 2010 11

Figure 5: UI Therapeutics Market, Global, Comparative Analysis of Adverse Events Associated With UI Therapeutic Drugs, 2010 12

Figure 6: UI Therapeutics Market, Global, Competitive Study On the Efficacy of Detrol LA, 2006 13

Figure 7: UI Therapeutics Market, Global, Competitive Study On the Efficacy of VESIcare, 2004-2005 19

Figure 8: UI Therapeutics Market, Global, Technology Trends Analytic Framework of the UI Therapeutics Pipeline, 2010 21

Figure 9: UI Therapeutics Market, Global, Technology Trends Analytic Framework of the UI Therapeutics Pipeline – Description, 2010 22

Figure 10: UI Therapeutics Market, Global, Clinical Pipeline by Mechanism of Action, 2010 25

Figure 11: UI Therapeutics Market, Global, Clinical Pipeline by Mechanism of Action, 2010 25

Figure 12: UI Therapeutics Market, Global, Implications for Future Market Competition in the UI Therapeutics Market, 2010 28

Figure 13: UI Therapeutics Market, Global, Clinical Pipeline by Company, 2010 29

Figure 14: GlobalData Methodology, 2010 40

Companies mentioned

Allergan Inc.

Astellas Pharma

Kissei Pharmaceuticals

Pfizer Inc.

To order this report:

Pharmaceutical Industry: Urinary Incontinence (UI) - Drug Pipeline Analysis and Market Forecasts to 2016

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

SOURCE Reportlinker